Showing results (51-60 of 76) with videos related to
Sort By:
Pageof 8
Current Oncology (Toronto, Ont.)|June 27, 2023
Prediction of Disease Progression to Upfront Pembrolizumab Monotherapy in Advanced Non-Small-Cell Lung Cancer with High PD-L1 Expression Using Baseline CT Disease Quantification and Smoking Pack YearsAli Silver, Cheryl Ho, Qian Ye, et al.Lung Cancer (Amsterdam, Netherlands)|August 28, 2024
Real-world treatment sequencing and effectiveness of second- and third-generation ALK tyrosine kinase inhibitors for ALK-positive advanced non-small cell lung cancerJessica R Bauman, Geoffrey Liu, Isabel Preeshagul, et al.Lung Cancer (Amsterdam, Netherlands)|August 6, 2021
The rapidly evolving landscape of novel targeted therapies in advanced non-small cell lung cancerBarbara Melosky, Paul Wheatley-Price, Rosalyn A Juergens, et al.Lung Cancer (Amsterdam, Netherlands)|December 9, 2019
Development, validation and results from the impact of treatment evolution in non-small cell lung cancer (iTEN) modelDaniel Moldaver, Manjusha Hurry, William K Evans, et al.Current Oncology (Toronto, Ont.)|July 25, 2022
Consensus Recommendations to Optimize Testing for New Targetable Alterations in Non-Small Cell Lung CancerDiana N Ionescu, Tracy L Stockley, Shantanu Banerji, et al.Therapeutic Advances in Medical Oncology|January 8, 2025
The continually evolving landscape of novel therapies in oncogene-driven advanced non-small-cell lung cancerBarbara Melosky, Rosalyn A Juergens, Shantanu Banerji, et al.Current Oncology (Toronto, Ont.)|December 22, 2023
Canadian Consensus Recommendations for the Management of Operable Stage II/III Non-Small-Cell Lung Cancer: Results of a Modified Delphi ProcessJames Tankel, Jonathan Spicer, Quincy Chu, et al.Current Oncology (Toronto, Ont.)|February 26, 2026
Early Experience with Tarlatamab (T-Cell Engagers) for Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Canada: Lessons Learned and Implementation StrategiesParneet K Cheema, Kirstin A Perdrizet, Randeep S Sangha, et al.Lung Cancer (Amsterdam, Netherlands)|September 18, 2025
Canadian Perspectives Revisited: Consensus on the management of ALK-rearranged NSCLCBarbara Melosky, Quincy S C Chu, Rosalyn A Juergens, et al.Current Oncology (Toronto, Ont.)|July 28, 2023
Lorlatinib Effectiveness and Quality-of-Life in Patients with ALK-Positive NSCLC Who Had Failed Second-Generation ALK Inhibitors: Canadian Real-World ExperienceMartin Rupp, Fiorella Fanton-Aita, Stephanie Snow, et al.Pageof 8